L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation
Open Access
- 18 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 105 (15), 1142-1150
- https://doi.org/10.1093/jnci/djt144
Abstract
Background Despite the excellent prognosis of Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage I, type I endometrial cancers, a substantial number of patients experience recurrence and die from this disease. We analyzed the value of immunohistochemical L1CAM determination to predict clinical outcome. Methods We conducted a retrospective multicenter cohort study to determine expression of L1CAM by immunohistochemistry in 1021 endometrial cancer specimens. The Kaplan–Meier method and Cox proportional hazard model were applied for survival and multivariable analyses. A machine-learning approach was used to validate variables for predicting recurrence and death. Results Of 1021 included cancers, 17.7% were rated L1CAM-positive. Of these L1CAM-positive cancers, 51.4% recurred during follow-up compared with 2.9% L1CAM-negative cancers. Patients bearing L1CAM-positive cancers had poorer disease-free and overall survival (two-sided Log-rank P < .001). Multivariable analyses revealed an increase in the likelihood of recurrence (hazard ratio [HR] = 16.33; 95% confidence interval [CI] = 10.55 to 25.28) and death (HR = 15.01; 95% CI = 9.28 to 24.26). In the L1CAM-negative cancers FIGO stage I subdivision, grading and risk assessment were irrelevant for predicting disease-free and overall survival. The prognostic relevance of these parameters was related strictly to L1CAM positivity. A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting recurrence (sensitivity = 0.74; specificity = 0.91) and death (sensitivity = 0.77; specificity = 0.89). Conclusions To our knowledge, L1CAM has been shown to be the best-ever published prognostic factor in FIGO stage I, type I endometrial cancers and shows clear superiority over the standardly used multifactor risk score. L1CAM expression in type I cancers indicates the need for adjuvant treatment. This adhesion molecule might serve as a treatment target for the fully humanized anti-L1CAM antibody currently under development for clinical use.Keywords
This publication has 42 references indexed in Scilit:
- L1CAM malfunction in the nervous system and human carcinomasCellular and Molecular Life Sciences, 2010
- Uterine papillary serous carcinoma: epidemiology, pathogenesis and managementCurrent Opinion in Obstetrics and Gynecology, 2010
- Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomasThe Journal of Pathology, 2009
- Endometrial Cancer State of the Science MeetingInternational Journal of Gynecologic Cancer, 2009
- L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomasThe Lancet, 2003
- Neural cell recognition molecule L1: from cell biology to human hereditary brain malformationsCurrent Opinion in Neurobiology, 1998
- Neural recognition molecules and synaptic plasticityCurrent Opinion in Cell Biology, 1997
- Mixed serous—endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinomaInternational Journal of Gynecologic Cancer, 1994
- Uterine Serous Carcinoma A Morphologically Diverse Neoplasm With Unifying Clinicopathologic FeaturesThe American Journal of Surgical Pathology, 1992
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983